Pacira BioSciences, Inc.
For the period ended Jun 30, 2025. Filed Aug 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 5, 2025
PCRX$36.46+0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| June 30,2025 | December 31,2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $300,484 | $276,774 |
| Short-term available-for-sale investments | 145,380 | 207,841 |
| Accounts receivable, net | 114,367 | 113,304 |
| Inventories, net | 148,163 | 125,282 |
| Prepaid expenses and other current assets | 37,219 | 21,929 |
| Total current assets | 745,613 | 745,130 |
| Fixed assets, net | 155,178 | 167,169 |
| Right-of-use assets, net | 46,528 | 49,222 |
| Goodwill | 20,300 | — |
| Intangible assets, net | 422,563 | 425,970 |
| Deferred tax assets | 128,270 | 130,376 |
| Investments and other assets | 18,810 | 35,649 |
| Total assets | $1,537,262 | $1,553,516 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $30,124 | $19,133 |
| Accrued expenses | 71,023 | 80,124 |
| Lease liabilities | 9,620 | 8,887 |
| Current portion of convertible senior notes, net | 202,397 | 201,776 |
| Total current liabilities | 313,164 | 309,920 |
| Convertible senior notes, net | 280,267 | 279,334 |
| Long-term debt, net | 97,828 | 104,211 |
| Lease liabilities | 41,291 | 44,645 |
| Contingent consideration | 17,209 | 20,241 |
| Deferred tax liabilities | 4,583 | — |
| Other liabilities | 25,153 | 16,817 |
| Total liabilities | 779,495 | 775,168 |
| Commitments and contingencies (Note 16) | ||
| Stockholders’ equity: | ||
| Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at June 30, 2025 and December 31, 2024 | — | — |
| Common stock, par value $0.001; 250,000,000 shares authorized; 47,690,595 shares issued and 44,897,766 shares outstanding at June 30, 2025 and 47,077,844 shares issued and 46,240,604 shares outstanding at December 31, 2024 | 48 | 47 |
| Treasury stock, at cost, inclusive of excise tax and broker fees, 2,792,829 and 837,240 shares at June 30, 2025 and December 31, 2024, respectively | (75,515) | (25,121) |
| Additional paid-in capital | 1,035,563 | 1,009,435 |
| Accumulated deficit | (206,391) | (206,356) |
| Accumulated other comprehensive income | 4,062 | 343 |
| Total stockholders’ equity | 757,767 | 778,348 |
| Total liabilities and stockholders’ equity | $1,537,262 | $1,553,516 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.